Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramipril + valsartan is a combination medication that combines an angiotensin-converting enzyme (ACE) inhibitor (ramipril) and an angiotensin II receptor blocker (ARB) (valsartan). This combination is used to treat hypertension (high blood pressure) and heart failure. Ramipril works by preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, helping relax blood vessels and reduce blood pressure. Valsartan works by blocking the binding of angiotensin II to its receptors, preventing blood vessel constriction and lowering blood pressure. However, it should be noted that using ACE inhibitors and ARBs together is generally not recommended by medical guidelines due to increased risk of adverse effects without significant additional benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ramipril + valsartan.